Drug Database
AL

aluminium hydroxide (Pangramin Depot)

✓ Approved

ALK-Abello · therapeutic agent

What is aluminium hydroxide?

aluminium hydroxide is a therapeutic agent developed by ALK-Abello. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesPangramin Depot
CompanyALK-Abello
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, ALK-Abello

Therapeutic Indications

aluminium hydroxide is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersRhinitis allergic✓ Approved

Related Research Articles

PubMedPediatric blood & cancer2026-07-25

Feasibility and Efficacy of Lorlatinib in Japanese Patients With Relapsed/Refractory ALK-Aberrant Neuroblastoma.

Imazu Takashi T, Kubota Hirohito H, Saida Satoshi S, Nishio Shuro S et al.

Lorlatinib, a third-generation ALK inhibitor, was administered off-label to five heavily pretreated patients with relapsed or refractory ALK-aberrant neuroblastoma. ALK alterations included F1174L, R1275Q, BEND5::ALK fusion, and ALK amplification; three patients had MYCN amplification. Best responses were three partial responses and two disease progressions. The longest progression-free survival (6.7 months) occurred in a patient with F1174L and non-amplified MYCN, whereas rapid progression was observed in two MYCN-amplified cases. Lorlatinib was generally well tolerated with manageable adverse events. These findings suggest that lorlatinib is a feasible therapeutic option in ALK-aberrant neuroblastoma and that clinical heterogeneity in treatment response warrants further investigation.

PMID 42499277
Read full article →
PubMedOncology letters2026-07-25

Association between the presence of EGFR or ALK mutations and the location of primary non-small cell lung cancer, as well as metabolic activity observed on 18F-FDG PET/CT scans.

Biner Inci Uslu IU, Cengiz Tuba Inal TI, Yilmaz Ulku U, Akyurek Nalan N et al.

The present study aimed to determine potential differences in tumor location and metabolism among patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements using 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT). Data from 18F-FDG PET/CT examinations of 112 patients with NSCLC were retrospectively reviewed. The maximum standardized uptake value (SUVmax), side (right or left), lobar localization (upper, middle or lower) and location (central or peripheral) of the lung mass were recorded. Differences in age, tumor diameter, location and SUVmax between the EGFR- and ALK-positive (+) groups were assessed. ALK and EGFR positivity were detected in 25.9% (n=29) and 74.1% (n=83) of patients, respectively. Analysis revealed comparable frequencies of EGFR mutations (42.2 vs. 57.8%) and ALK rearrangements (44.8 vs. 55.2%) in peripheral and central tumors, respectively. Of the patients with ALK(+), 11 (37.9%) tumors were located on the left and 18 (62.1%) on the right, whereas in EGFR(+) patients, 39 (47.0%) were located on the left and 44 (53.0%) on the right. EGFR+ and ALK(+) tumors were more prevalent in the upper lobe (58.6 and 60.2%, respectively). No significant association was found between the side of the main tumor, lobar position, location type and the occurrence of ALK rearrangements or EGFR mutations (P=0.530, P=0.147 and P=0.975, respectively). Mutation status was not associated with median SUVmax of the primary tumor (P=0.451), No significant difference in tumor size was observed between the groups (P=0.472) and there was no association between patient age and mutation status (P=0.422). In conclusion, tumor localization and SUVmax derived from 18F-FDG PET/CT data yielded limited utility in differentiating EGFR-mutant and ALK-rearranged NSCLC. These findings should be validated in larger multicenter cohorts.

PMID 42500605
Read full article →
PubMedSmart molecules : open access2026-07-25

Unlocking n-alk-1-ynes conformers: Quantum "trigger finger" versus "stiff joint" conformations.

Bâldea Ioan I

Molecular conformation in n-alk-1-ynes (CnA) is conventionally simplified to an all-planar structure. We report a comprehensive quantum chemical analysis revealing two near-isoenergetic rotamers at the acetylenic terminus: planar ( C s ) and skewed ( C 1 ). The high, symmetric rotational energy barrier ( ≈ 150   meV) arises from unique steric relief near the s p center coupled with electronic stabilization of C 1 . This creates a unique kinetic profile: a Quantum "Trigger Finger" ( α rotation) that enforces an ≈ 50 % : 50 % C s / C 1 ensemble, sharply contrasting with the thermodynamically biased "Stiff Joint" ( δ rotation) of the alkyl chain. This structural degeneracy necessitates ensemble averaging for spectroscopic data interpretation, while the slow interconversion permits kinetic trapping and intentional conformer enrichment during synthesis and molecular junction fabrication. Our work redefines the alkyne anchor, providing a blueprint for accurate interpretation of spectroscopic data and achieving conformational control in molecular electronics.

PMID 42500734
Read full article →
PubMedCancer treatment and research communications2026-07-25

Comprehensive molecular profiling of advanced NSCLC in Greek patients:A prospective HeCOG study.

Kosmidis Paris A PA, Kosmidis Thanos T, Papadopoulou Kyriaki K, Korfiatis Nikolaos N et al.

We report for the first time the molecular landscape and outcome associations from the prospective CLIMEDIN trial in Greece. Two hundred patients with newly diagnosed advanced NSCLC (March 2022-October 2023) were enrolled and randomized to standard-of-care education versus additional automated, adverse-event-targeted digital interventions. Within this study baseline testing (EGFR, ALK, PD-L1) was performed in all; 165 tumors underwent comprehensive NGS (Oncomine Comprehensive Assay v3). Primary endpoint was improvement in AEs/QoL; secondary endpoints included ORR, PFS and OS. Associations between genomic alterations and outcomes were explored. Median age was 68 years; 75% male; 52% current smokers; adenocarcinoma 68.5%. Most received chemo-immunotherapy (66%). At data cut-off (December 2025; reverse-Kaplan-Meier median follow-up 36.3 months), median PFS was 9.6 months and median OS was 15.2 months. Across 200 tumors, 495 pathogenic variants (PVs) were identified in 83 genes. Exploratory outcome analyses showed longer OS in EGFR-mutant disease (preserved under parsimonious multivariable adjustment) and a formal KRAS × smoking interaction for OS (interaction P = 0.011). In this cohort, the molecular profile mirrors other Caucasian series, with clinically relevant enrichment patterns for EGFR and KRAS. ECOG performance status and first line treatment were the dominant prognostic factors in this cohort. A novel KRAS and smoking interaction for overall survival warrants prospective validation.

PMID 42497607
Read full article →
PubMedEnvironmental research2026-07-25

Electrochemical Crystallization Transforms Labile Sediment Phosphorus into Stable Crystalline Vivianite.

Mei Weiqing W, Chen Yiyang Y, Tan Xinjie X, Bu Hongling H et al.

Internal phosphorus (P) loading from sediments remains a major bottleneck for the long-term remediation of eutrophic waters. Although electrochemical strategies for vivianite (Fe3(PO4)2·8H2O) formation show promise for phosphate removal from wastewater, they typically rely on precise pH control, severely limiting their potential for in situ application in complex natural sediments. Here, a low-current-density electrochemical system is reported that directs labile sedimentary P toward crystalline vivianite under bulk aerobic laboratory conditions. Using iron electrodes at 1 mA cm-2, 32% of sedimentary P and 37% of aqueous-system P were converted into vivianite-bound P, within the range reported for authigenic vivianite in Fe-rich, low-sulfidation sediments. Increasing current density accelerated P immobilization but shifted the products toward ferrihydrite-adsorbed P and amorphous Fe-P. XANES and EXAFS showed that low current density preserved Fe(II)-rich products with higher Fe-centered connectivity, whereas higher current densities promoted Fe oxidation and structural disordering. Complementary XRD, XPS, FTIR, Raman, and SEM-EDS supported the formation of layered Fe-P particles with Fe/P ratios close to vivianite stoichiometry at low current density. The low-current condition maintained a favorable pH evolution and sustained Fe2+ supply, thereby favoring Fe(II)-phosphate crystallization over Fe hydroxide/amorphous Fe-P formation. This work demonstrates a charge-quantified, pathway-selective electrochemical mineralization strategy for converting labile sedimentary P into crystalline Fe(II)-phosphate under controlled sediment-water conditions.

PMID 42498108
Read full article →
PubMedJournal of environmental sciences (China)2026-07-25

Phosphorus capture from subsurface drainage water using iron-activated alumina (Alcan): Column adsorption, regeneration, and agronomic reuse evaluation.

Kumari Soni S, Dong Younsuk Y

This study investigates the column adsorption and regeneration performance of iron-activated alumina (Alcan) for phosphate removal from subsurface drainage water under dynamic flow conditions. Continuous-flow fixed-bed column experiments were conducted at three empty bed contact times (EBCTs) of 5, 10, and 15 min using synthetic subsurface drainage water with 2 mg/L phosphate. Saturated media were regenerated using 0.1 mol/L potassium hydroxide (KOH), and adsorption-desorption cycles were repeated to assess reusability. Results showed that > 90 % phosphate recovery was achieved during 1st desorption cycle at 120 and 40 pore volumes for 5 and 10 min EBCTs, respectively. However, second-cycle adsorption showed reduced performance, notably 72 % phosphate recovery at 5 min EBCT due to residual phosphate and structural degradation. ICP-OES and FE-SEM analysis confirmed elemental leaching and morphological changes post-regeneration. A cost benefit analysis demonstrated a competitive treatment cost of $829/kg P removed. Furthermore, agronomic evaluation of P-saturated media indicated comparable results to conventional diammonium phosphate (DAP), supporting its dual functionality as a slow-release P fertilizer. Despite performance loss, Alcan demonstrated high initial adsorption capacity and partial reusability, suggesting potential as a recyclable adsorbent and a slow-release phosphate source in sustainable nutrient management strategies. This study uniquely integrates dynamic column adsorption, alkaline regeneration, and agronomic reuse evaluation of iron-activated alumina (Alcan) for phosphorus capture from subsurface drainage water, presenting a closed-loop, circular approach that bridges water treatment with nutrient recovery.

PMID 42498380
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about aluminium hydroxide